Parse

Parse indexes AI recommendations so brands know where they stand.

Products

  • Brands
  • Markets
  • Integrations
  • Work with us
  • Pricing
  • MCP

Resources

  • Research
  • Methodology
  • Blog

© 2026 Parse. All rights reserved.

LegalPrivacy PolicyTerms of Service
Parse
Work with usPricing
Sign inCheck your brand
  1. Brands
  2. Triomics
BrandsTriomics

How AI describes Triomics

Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this

Triomics logoTriomicstriomics.com

Triomics provides a generative AI platform for cancer care providers that automatically screens patient appointments against clinical trial portfolios and assembles expert-level patient snapshots. The platform helps accelerate trial enrollment, streamline healthcare operations, and improve data curation with high accuracy.

Parse Score

42.5

#31 of 41 in Clinical Trial Feasibility Software

Strength7
Reach29
Authority17

Work at Triomics?

Claim this profile for the full report: every prompt where Triomics appears, who is gaining, and what AI says about you. Claiming is free and unlocks your brand’s ambient view. Monitoring a market is the paid layer on top.

Verified with a work email.

Track this weekly.

Monitor Triomics

Sources

triomics.com shapes more of what AI says about Triomics than any other source, at 67% of its citations.

asco.org

AI questions where Triomics appears

Always know where you stand in AI

Start monitoring Triomics

The market map

Clinical Trial Feasibility Software →
5%10%20%50%Category leadersSpecialistsIn the mixLong tailNamed in more AI answers →Appears earlier in the answer →SASDeep 6 AICertaraBerry ConsultantsVerana HealthIQVIATriNetXTempusCytelBEK HealthInovalonEpicinterAdaptFlatiron HealthTriomics

Where AI ranks Triomics

Clinical Trial Feasibility Software#31

  • Excerpts where Triomics appeared in the AI's answer

    Google AI Mode · excerpt
    Triomics PRISM — Employs domain-specific large language models (such as OncoLLM) to prospectively screen upcoming patient visits against active cancer trial portfolios, drastically reducing manual chart review time.